Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -31.70% is in line with its 5-year average of -34.36%, near the low end of its 5-year range (-48.16%–28.70%).
As of the fiscal period ended Tuesday, June 30, 2026. 655.17% below its 12-month average of -4.20%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -31.70%.
RETURN ON EQUITY (ROE)
-31.70%
RETURN ON EQUITY (ROE) AVG TTM
-4.20%
RETURN ON EQUITY (ROE) AVG 3Y
-22.73%
RETURN ON EQUITY (ROE) AVG 5Y
-34.36%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-655.17%
CURRENT VS 3Y AVG
-39.47%
CURRENT VS 5Y AVG
+7.73%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.09%
median of 523 covered companies
CURRENT VS SECTOR MEDIAN
+20.92%
vs the sector median at left
Keros Therapeutics, Inc.
Market Cap
$224.34M
Return on Equity (ROE)
-31.70%
TTM Avg
-4.20%
3Y Avg
-22.73%
5Y Avg
-34.36%
Market Cap
$225.24M
Return on Equity (ROE)
-43.11%
TTM Avg
-35.75%
3Y Avg
-28.47%
5Y Avg
-12.53%
Market Cap
$229.78M
Return on Equity (ROE)
-34.04%
TTM Avg
-95.97%
3Y Avg
-70.55%
5Y Avg
-68.40%
Market Cap
$230.29M
Return on Equity (ROE)
-303.61%
TTM Avg
612.49%
3Y Avg
-57.80%
5Y Avg
-87.69%
Market Cap
$218.14M
Return on Equity (ROE)
21.24%
TTM Avg
17.52%
3Y Avg
32.51%
5Y Avg
46.01%
Market Cap
$233.80M
Return on Equity (ROE)
-25.20%
TTM Avg
-25.82%
3Y Avg
5.12%
5Y Avg
5.12%
Market Cap
$214.64M
Return on Equity (ROE)
19.38%
TTM Avg
20.63%
3Y Avg
-8.44%
5Y Avg
-40.10%
Market Cap
$215.11M
Return on Equity (ROE)
39.66%
TTM Avg
4.24%
3Y Avg
-15.88%
5Y Avg
-20.06%
Market Cap
$236.09M
Return on Equity (ROE)
-118.58%
TTM Avg
62.37%
3Y Avg
-376.78%
5Y Avg
-340.60%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | $224.34M | -31.70% | -4.20% | -22.73% | -34.36% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $225.24M | -43.11% | -35.75% | -28.47% | -12.53% |
| MacroGenics, Inc. (MGNX)vs › | $229.78M | -34.04% | -95.97% | -70.55% | -68.40% |
| Biodesix, Inc. (BDSX)vs › | $230.29M | -303.61% | 612.49% | -57.80% | -87.69% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $218.14M | 21.24% | 17.52% | 32.51% | 46.01% |
| BioAge Labs Inc. (BIOA)vs › | $233.80M | -25.20% | -25.82% | 5.12% | 5.12% |
| Niagen Bioscience Inc (NAGE)vs › | $214.64M | 19.38% | 20.63% | -8.44% | -40.10% |
| Compugen Ltd. (CGEN)vs › | $215.11M | 39.66% | 4.24% | -15.88% | -20.06% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $236.09M | -118.58% | 62.37% | -376.78% | -340.60% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $212.09M | -106.27% | -100.08% | -64.49% | -52.22% |
ROE
-31.7%
ROA
-28.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -31.70% |
| 2026-03-31 | -29.81% |
| 2025-12-31 | 28.70% |
| 2025-09-30 | 9.16% |
| 2025-06-30 | 2.66% |
| 2025-03-31 | 0.58% |
| 2024-12-31 | -32.78% |
| 2024-09-30 | -34.08% |
| 2024-06-30 | -39.93% |
| 2024-03-31 | -35.31% |
| 2023-12-31 | -46.05% |
| 2023-09-30 | -48.16% |
| 2023-06-30 | -38.78% |
| 2023-03-31 | -32.76% |
| 2022-12-31 | -37.73% |
| 2022-09-30 | -33.98% |
| 2022-06-30 | -37.26% |
| 2022-03-31 | -30.00% |
| 2021-12-31 | -24.16% |
| 2021-09-30 | -28.60% |
| 2021-06-30 | -23.01% |
| 2021-03-31 | -19.87% |
| 2020-12-31 | -17.33% |
| 2020-09-30 | -28.63% |
| 2020-06-30 | -20.48% |
